Table 3.

Analysis of subgroups as defined by each baseline variable

Baseline characteristic	Recorded number of patients with gastric or duodenal ulcer		Cox regression analysis
	Lansoprazole	Gefarnate	Hazard ratio (95% CI)	P value
H. pylori status
Positive	6/81a	27/87b	0.1798 (0.0740–0.4369)	<0.0001
Negative	9/87a	19/75b	0.3327 (0.1504–0.7361)	0.0044
CYP2C19
PM	4/30c	7/32d	0.4675 (0.1360–1.6070)	0.2167
EM	10/124c	30/112d	0.2408 (0.1176–0.4929)	<0.0001
Age (years)
25–64	7/86	20/83	0.2254 (0.0946–0.5370)	0.0002
65–85	8/82	26/79	0.2766 (0.1251–0.6112)	0.0007
Smoking status
Yes	5/48	19/60	0.2262 (0.0840–0.6088)	0.0014
No	10/120	27/102	0.2649 (0.1281–0.5481)	0.0001
Alcohol consumption
Yes	5/57	16/63	0.2873 (0.1048–0.7877)	0.0096
No	10/111	30/99	0.2377 (0.1161–0.4866)	<0.0001
Underlying disease
Rheumatoid arthritis
Yes	7/68	21/67	0.2342 (0.0993–0.5522)	0.0003
No	8/100	25/95	0.2664 (0.1201–0.5913)	0.0005
Osteoarthritis
Yes	4/59	17/58	0.1904 (0.0640–0.5665)	0.0009
No	11/109	29/104	0.2860 (0.1426–0.5734)	0.0002

Data are presented as numbers at risk

At risk: the number of patients at risk included all full analysis set patients who had at least one post-randomization endoscopy assessment, and had no acute-stage or healing-stage gastric or duodenal ulcer as confirmed by the Independent Adjudication Committee

Results of Cox regression analyses in lansoprazole or gefarnate group, respectively, between each group indicated (H. pylori-positive vs. -negative and CYP2C19 PM vs. EM); hazard ratio (95% CI) and P value

PM poor metabolizers, EM extensive metabolizers

^a H. pylori-positive vs. -negative; 0.6306 (0.2240–1.7750), P = 0.3825

^b H. pylori-positive vs. -negative; 1.1418 (0.6338–2.0571), P = 0.6588

^cPM vs. EM; 0.6890 (0.2160–2.1977), P = 0.5291

^dPM vs. EM; 1.2611 (0.5520–2.8812), P = 0.5821